Advertisement

Clinical Research in Cardiology

, Volume 108, Issue 10, pp 1128–1139 | Cite as

Cardioprotective effect of renin–angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity

  • Kisho OhtaniEmail author
  • Tomomi Ide
  • Ken-ichi Hiasa
  • Ichiro Sakamoto
  • Nami Yamashita
  • Makoto Kubo
  • Hiroyuki Tsutsui
Original Paper

Abstract

Background

Trastuzumab-related cardiotoxicity (TRC) has been considered as reversible. However, recent studies have raised concern against reversibility of left ventricular (LV) systolic dysfunction in breast cancer patients treated with trastuzumab. In addition, the efficacy of medical treatment for heart failure (HF) including renin–angiotensin inhibitors and β-blockers has not been defined in TRC.

Methods and results

We retrospectively studied 160 patients with breast cancer receiving trastuzumab in the adjuvant (n = 129) as well as metastatic (n = 31) settings in our institution from 2006 to 2015. During the median follow-up of 3.5 years, 20 patients (15.5%) receiving adjuvant trastuzumab and 7 patients (22.6%) with metastatic breast cancer developed TRC with a mean decrease in LV ejection fraction (EF) of 19.8%. By the multivariate analysis, lower LVEF before trastuzumab (OR 1.30; 95% CI 1.16–1.48; P = 0.0001) independently predicted subsequent development of TRC. LV systolic dysfunction was reversible in 20 patients (74.1%) with a median time to recovery of 7 months, which was independently associated with lower dose of anthracyclines (OR 1.03; 95% CI 1.01–1.07, P = 0.020) and an introduction of renin–angiotensin inhibitors and β-blockers (OR 19.0; 95% CI 1.00–592.2, P = 0.034).

Conclusions

Irreversible decline in LVEF occurred in patients who underwent trastuzumab in combination with anthracyclines with a relatively high frequency. The lower cumulative dose of anthracyclines and HF treatment including renin–angiotensin inhibitors and β-blockers were both independent predictors to enhance LV functional reversibility in patients with TRC.

Keywords

β-blockers Cardiotoxicity Reversibility Heart failure Renin–angiotensin inhibitors Trastuzumab 

Notes

Acknowledgements

We thank Chie Tada, Youko Matsuura, Gorou Kawahara, Shiori Horikawa, Tokiko Hirakawa, Sayaka Ohtake, Tasuku Satoh, Aki Katsuki, Maki Tsutsumi, Asami Hanada, Nami Kuwano for the assistance in echocardiographic data collection.

Funding

This study was supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (K.O., T.I.).

Compliance with ethical standards

Conflict of interest

Dr. Tsutsui has received the research grant from Actelion, Daichii-Sankyo, and Astellas, and lecture fees from Astellas, Otsuka, Takeda, Daichii-Sankyo, Mitsubishi Tanabe, Boehringer Ingelheim, Novartis, Bayer, and Bristol-Myers Squibb.

References

  1. 1.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefGoogle Scholar
  2. 2.
    Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24(36):5658–5663.  https://doi.org/10.1200/JCO.2006.07.0250 CrossRefPubMedGoogle Scholar
  3. 3.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, team Hs (2007) 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36.  https://doi.org/10.1016/S0140-6736(07)60028-2 CrossRefGoogle Scholar
  4. 4.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792.  https://doi.org/10.1056/NEJM200103153441101 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672.  https://doi.org/10.1056/NEJMoa052306 CrossRefPubMedGoogle Scholar
  6. 6.
    Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O’Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265–4274.  https://doi.org/10.1200/JCO.2005.04.173 CrossRefGoogle Scholar
  7. 7.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684.  https://doi.org/10.1056/NEJMoa052122 CrossRefPubMedGoogle Scholar
  8. 8.
    Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5(4):154–166.  https://doi.org/10.1177/2042098614529603 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106(1):35–46.  https://doi.org/10.1161/CIRCRESAHA.109.205906 CrossRefPubMedGoogle Scholar
  10. 10.
    Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ (2016) Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther 15(6):1321–1331.  https://doi.org/10.1158/1535-7163.MCT-15-0741 CrossRefPubMedGoogle Scholar
  11. 11.
    Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284(4):2080–2087.  https://doi.org/10.1074/jbc.M804570200 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23(13):2900–2902.  https://doi.org/10.1200/JCO.2005.05.827 CrossRefPubMedGoogle Scholar
  13. 13.
    Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD006243.pub2 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nole F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916.  https://doi.org/10.1200/JCO.2009.27.3615 CrossRefPubMedGoogle Scholar
  15. 15.
    Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3525–3533.  https://doi.org/10.1200/JCO.2007.11.0106 CrossRefPubMedGoogle Scholar
  16. 16.
    Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol 28(21):3422–3428.  https://doi.org/10.1200/JCO.2009.26.0463 CrossRefPubMedGoogle Scholar
  17. 17.
    Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107–4115.  https://doi.org/10.1200/JCO.2005.04.9551 CrossRefPubMedGoogle Scholar
  18. 18.
    Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900–2909.  https://doi.org/10.1016/j.ejca.2013.04.030 CrossRefPubMedGoogle Scholar
  19. 19.
    Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K, Tsutsui H (2018) Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol.  https://doi.org/10.1007/s00392-018-1386-0 CrossRefPubMedGoogle Scholar
  20. 20.
    Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911–939.  https://doi.org/10.1016/j.echo.2014.07.012 CrossRefPubMedGoogle Scholar
  21. 21.
    Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research G (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283.  https://doi.org/10.1056/NEJMoa0910383 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32(20):2159–2165.  https://doi.org/10.1200/JCO.2013.53.9288 CrossRefPubMedGoogle Scholar
  23. 23.
    Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900–905.  https://doi.org/10.1056/NEJM199809243391307 CrossRefPubMedGoogle Scholar
  24. 24.
    Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815.  https://doi.org/10.1200/JCO.2006.10.4976 CrossRefPubMedGoogle Scholar
  25. 25.
    Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819.  https://doi.org/10.1200/JCO.2005.02.4091 CrossRefPubMedGoogle Scholar
  26. 26.
    Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50(15):1435–1441.  https://doi.org/10.1016/j.jacc.2007.06.037 CrossRefPubMedGoogle Scholar
  27. 27.
    Bersell K, Arab S, Haring B, Kuhn B (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2):257–270.  https://doi.org/10.1016/j.cell.2009.04.060 CrossRefPubMedGoogle Scholar
  28. 28.
    Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603.  https://doi.org/10.1161/CIRCIMAGING.112.973321 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99(9):634–639.  https://doi.org/10.1136/heartjnl-2012-303151 CrossRefPubMedGoogle Scholar
  30. 30.
    Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, Lee DS (2016) Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol 34(19):2239–2246.  https://doi.org/10.1200/JCO.2015.65.1505 CrossRefPubMedGoogle Scholar
  31. 31.
    Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504–2512.  https://doi.org/10.1016/j.jacc.2012.07.068 CrossRefPubMedGoogle Scholar
  32. 32.
    Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792–3799.  https://doi.org/10.1200/JCO.2011.40.0010 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK (2016) Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Res Treat 157(3):535–544.  https://doi.org/10.1007/s10549-016-3823-y CrossRefPubMedGoogle Scholar
  34. 34.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A, Investigators Pt (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748.  https://doi.org/10.1016/S1470-2045(13)70225-0 CrossRefPubMedGoogle Scholar
  35. 35.
    Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V, Breast Cancer Investigators of Hellenic Oncology Research Group AG (2015) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 26(7):1333–1340.  https://doi.org/10.1093/annonc/mdv213 CrossRefPubMedGoogle Scholar
  36. 36.
    Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B (2017) Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135(15):1397–1412.  https://doi.org/10.1161/CIRCULATIONAHA.116.023463 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D’Alessio G, De Lorenzo C (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23(9):3171–3178.  https://doi.org/10.1096/fj.09-131383 CrossRefPubMedGoogle Scholar
  38. 38.
    Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM (2016) Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2(1):29–36.  https://doi.org/10.1001/jamaoncol.2015.3709 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK (2016) The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djv301 CrossRefPubMedGoogle Scholar
  40. 40.
    Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH (2013) Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 6(3):420–426.  https://doi.org/10.1161/CIRCHEARTFAILURE.112.000055 CrossRefPubMedGoogle Scholar
  41. 41.
    Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35(8):870–877.  https://doi.org/10.1200/JCO.2016.68.7830 CrossRefPubMedGoogle Scholar
  42. 42.
    Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671–1680.  https://doi.org/10.1093/eurheartj/ehw022 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH (2016) Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2(8):1030–1037.  https://doi.org/10.1001/jamaoncol.2016.1726 CrossRefPubMedGoogle Scholar
  44. 44.
    Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31):7820–7826.  https://doi.org/10.1200/JCO.2005.13.300 CrossRefPubMedGoogle Scholar
  45. 45.
    Tilemann LM, Heckmann MB, Katus HA, Lehmann LH, Muller OJ (2018) Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107(4):271–280.  https://doi.org/10.1007/s00392-018-1202-x CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kisho Ohtani
    • 1
    Email author
  • Tomomi Ide
    • 1
  • Ken-ichi Hiasa
    • 1
  • Ichiro Sakamoto
    • 1
  • Nami Yamashita
    • 2
  • Makoto Kubo
    • 3
  • Hiroyuki Tsutsui
    • 1
  1. 1.Department of Cardiovascular Medicine, Faculty of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of Surgery and Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations